Single Dose Study To Study The Absorption, Metabolism And Excretion Of Famitinib

NCT05473468 | Unknown Phase 1

• 1 other identifier: FMTN-I-107
• Study Type: interventional
• Target: 6
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to evaluate the excretion balance, metabolic profile and the routes of excretion of famitinib in healthy adult male subjects.

Conditions

Healthy Subjects

Outcome Measures

Primary Outcomes (15)

• Mass balance recovery of total radioactivity in all excreta urine: CumAe and Cum%Ae

  Amount and cumulative amount excreted and expressed as the percentage of the administered dose into the urine from time t1 to time t2

  0-336 hours

• Mass balance recovery of total radioactivity in all excreta feces: CumAe and Cum%Ae

  Amount and cumulative amount excreted and expressed as the percentage of the administered dose into the feces from time t1 to time t2

  0-336 hours

• Total recovery of radioactivity in urine and feces as percentage of total radioactive dose administered

  To characterize the extent of excretion of total radioactivity in urine and feces following administration of famitinib

  0-336 hours

• Metabolic Profiling in Blood

  Metabolic profiling/identification and determination of relative abundance of famitinib and the metabolites of famitinib in plasma if possible.

  0 to 240 hours

• Metabolic Profiling in Urine

  Metabolic profiling/identification and determination of relative abundance of famitinib and the metabolites of famitinib in urine if possible.

  0-336 hours

• Metabolic Profiling in Feces

  Metabolic profiling/identification and determination of relative abundance of famitinib and the metabolites of famitinib in feces if possible.

  0-336 hours

• Ratio of radioactivity of whole blood and plasma blood

  0-72 hours

• Radioactivity AUC

  0-240 hours

• Plasma famitinib and SHR116637: AUC

  0-240 hours

• Plasma famitinib and SHR116637: Cmax

  0-240 hours

• Plasma famitinib and SHR116637: Tmax

  0-240 hours

• Radioactivity Tmax

  0-240 hours

• Radioactivity Cmax

  0-240 hours

• Plasma famitinib and SHR116637: t1/2

  0-240 hours

• Radioactivity t1/2

  0-240 hours

Secondary Outcomes (1)

• AEs and SAEs

  0-14 days

Study Arms (1)

Treatment group

EXPERIMENTAL

Drug: Famitinib

Interventions

Famitinib DRUG

a single oral dose of \[14C\]famitinib (25 mg/150 uCi suspension)

Treatment group

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy adult male between the ages of 18 and 45 years;
• Total body weight ≥ 50 kg, and the Body Mass Index (BMI) of 19 to 28 kg/m2;
• Male subjects of childbearing potential and their partners have no birth or sperm donation plan and voluntarily take effective contraception during the course of clinical trial until 6 months after the drug administration;
• An informed consent document signed and dated by the subject;
• Normal bowel movements (1 to 2 times a day), no habitual constipation or diarrhea.

You may not qualify if:

• No clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests;
• Positive results of hepatitis B surface antigen, hepatitis C antibody, HIV antibody or treponema pallidum antibody;
• Have taken any clinical trial drug or participated in any clinical trial within 3 months before administration;
• CYP3A4 inducers or inhibitors were taken within 28 days before administration;
• Have taken any prescription or over-the-counter drugs, vitamin products, health care drugs, traditional Chinese medicines or food supplements within 14 days before administration;
• Those who need to receive anticoagulant therapy such as warfarin or thrombin inhibitors and/or aspirin antiplatelet therapy within 1 month before administration and during the study period;
• There are clinically significant bleeding symptoms or clear bleeding tendencies within 3 months before administration, such as gastrointestinal bleeding and peptic ulcers;
• History of stroke or intracranial hemorrhage within 6 months before administration;
• Have uncontrolled clinical symptoms or diseases of the heart, such as: (1) heart failure above NYHA2 (2) unstable angina (3) myocardial infarction within 1 year (4) clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention (5) screening period QTcF \>450 ms (male);
• Those who have undergone major surgery within 6 months before administration or that surgical incision has not completely healed; Major surgery includes, but is not limited to, any surgery that is at significant risk of bleeding, prolongs the period of general anesthesia, or has an incision biopsy or significant traumatic injury;
• Abdominal fistula, gastrointestinal perforation or abdominal abscess occurred within 6 months before administration;
• Hemorrhoids or perianal diseases accompanied by regular / hematochezia; Those with gastrointestinal abnormalities such as irritable bowel syndrome and inflammatory bowel disease, which may affect drug absorption as determined by investigator;
• People with allergic constitution or allergic diseases, including those with severe drug allergies or history of drug allergies, and those who are known to be allergic to famitinib or excipients;
• Have any history of clinical serious diseases or diseases or conditions that the researcher believes may affect the results of the trial, including but not limited to circulatory system, endocrine system, nervous system, digestive system, urinary system or blood, immune, psychiatric and metabolic disease history; Lifestyle Habits;
• History of alcoholism with alcohol consumption over 14 units per week;; and can't abstain from smoking and alcohol during the study;

Sponsors & Collaborators

• Jiangsu HengRui Medicine Co., Ltd.: lead

Study Sites (1)

Shanghai Xuhui District Central Hospital

Shanghai, Shanghai Municipality, 200000, China

Location

MeSH Terms

Interventions

famitinib

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Single oral dose of \[14c\]-Famitinib

Study Record Dates

• First Submitted: July 20, 2022
• First Posted: July 26, 2022
• Study Start: August 26, 2022
• Primary Completion: November 1, 2022
• Study Completion: November 1, 2022
• Last Updated: November 2, 2022

Record last verified: 2022-11

Locations

CN (1)